Clinical Trial Update: Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease [NA]

View source ↗

Summary

The University of Hong Kong conducted a completed clinical trial evaluating oral paricalcitol for patients with stage 3-5 chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: The University of Hong Kong | Conditions: Chronic Kidney Disease | NA | Status: COMPLETED